Endoscopy 2014; 46(02): 120-126
DOI: 10.1055/s-0034-1364872
Original article
© Georg Thieme Verlag KG Stuttgart · New York

Antireflux stents to reduce the risk of cholangitis in patients with malignant biliary strictures: a randomized trial

Bing Hu
Department of Endoscopy, Eastern Hepatobiliary Hospital, Second Military Medical University, Shanghai, China
Tian-tian Wang
Department of Endoscopy, Eastern Hepatobiliary Hospital, Second Military Medical University, Shanghai, China
Jun Wu
Department of Endoscopy, Eastern Hepatobiliary Hospital, Second Military Medical University, Shanghai, China
Zhi-mei Shi
Department of Endoscopy, Eastern Hepatobiliary Hospital, Second Military Medical University, Shanghai, China
Dao-jian Gao
Department of Endoscopy, Eastern Hepatobiliary Hospital, Second Military Medical University, Shanghai, China
Ya-min Pan
Department of Endoscopy, Eastern Hepatobiliary Hospital, Second Military Medical University, Shanghai, China
› Author Affiliations
Further Information

Publication History

submitted 17 May 2013

accepted after revision 08 December 2013

Publication Date:
29 January 2014 (online)

Background and study aims: There are limited data on the role of antireflux biliary stents. This single-center randomized trial compared the endoscopic use of partly covered antireflux metal stents (pcARMS) with that of standard uncovered self-expandable metal stents (ucSEMS) for the palliation of nonhilar malignant biliary obstruction.

Patients and methods: Between August 2007 and February 2012, patients with nonhilar malignant biliary obstruction were randomly assigned to treatment with either pcARMS or ucSEMS. Subsequent follow-up was conducted in clinic or by phone. The primary outcome was onset of cholangitis within 12 months of stenting. Secondary outcomes included other morbidities, stent dysfunctions, and survival.

Results: Altogether 112 patients were included, 56 in each group. The stents were successfully deployed in all patients. Satisfactory jaundice control was achieved in 49 cases in the pcARMS group, compared with 47 in the ucSEMS group (P = 0.135). Fewer patients experienced cholangitis in the pcARMS group than in the ucSEMS group (10 vs. 21 patients; P = 0.035), and the frequency of episodes was less (P = 0.022). Respectively, 17 and 29 stent dysfunctions before death were observed in the pcARMS and ucSEMS groups (P = 0.051) and the median stent patency was 13.0 (standard deviation [SD] 3.4) and 10.0 (1.2) months, respectively (P = 0.044). At final follow-up, in January 2013, 50 /52 and 52 /55 patients had died and no difference in median survival was seen between the two groups (8.0 vs. 9.0 months, P = 0.56).

Conclusions: Stenting with pcARMS compared with standard ucSEMS reduces risk of ascending cholangitis and has longer stent patency, but does not increase patient survival.

Chictr.org. number, ChiCTR-TRC-11001800.

  • References

  • 1 Adler DG, Baron TH, Davila RE et al. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas. Gastrointest Endosc 2005; 621-628
  • 2 Dumonceau JM, Tringali A, Blero D et al. Biliary stenting: indications, choice of stents and results: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. Endoscopy 2012; 44: 277-298
  • 3 Cheng JL, Bruno MJ, Bergman JJ et al. Endoscopic palliation of patients with biliary obstruction caused by nonresectable hilar cholangiocarcinoma: efficacy of self-expandable metallic Wallstents. Gastrointest Endosc 2002; 56: 33-39
  • 4 Yoon W, Ryu J, Yang K et al. A comparison of metal and plastic stents for the relief of jaundice in unresectable malignant biliary obstruction in Korea: an emphasis on cost-effectiveness in a country with a low ERCP cost. Gastrointest Endosc 2009; 70: 284-289
  • 5 Wasan SM, Ross WA, Staerkel GA et al. Use of expandable metallic biliary stents in resectable pancreatic cancer. Am J Gastroenterol 2005; 100: 2056-2061
  • 6 Okamoto T, Fujioka S, Yanagisawa S et al. Placement of a metallic stent across the main duodenal papilla may predispose to cholangitis. Gastrointest Endosc 2006; 63: 792-796
  • 7 Misra SP, Dwivedi M. Reflux of duodenal contents and cholangitis in patients undergoing self-expanding metal stent placement. Gastrointest Endosc 2009; 70: 317-321
  • 8 Hu B, Wang TT, Shi ZM et al. A novel antireflux metal stent for the palliation of biliary malignancies: a pilot feasibility study (with video). Gastrointest Endosc 2011; 73: 143-148
  • 9 Dua KS, Reddy ND, Rao VG et al. Impact of reducing duodenobiliary reflux on biliary stent patency: an in vitro evaluation and a prospective randomized clinical trial that used a biliary stent with an antireflux valve. Gastrointest Endosc 2007; 65: 819-828
  • 10 Kahaleh M. Antireflux biliary stents: is it time to go with the flow?. Gastrointest Endosc 2007; 65: 829-831
  • 11 Hamada T, Isayama H, Nakai Y et al. Novel antireflux covered metal stent for recurrent occlusion of biliary metal stents: A pilot study. Dig Endosc 2013; (Epub Apr 29 2013)
  • 12 Lee KJ, Chung MJ, Park JY et al. Clinical advantages of a metal stent with an S-shaped anti-reflux valve in malignant biliary obstruction. Dig Endosc 2013; 25: 308-312
  • 13 Dowidar N, Kolmos HJ, Lyon H et al. Clogging of biliary endoprostheses. A morphologic and bacteriologic study. Scand J Gastroenterol 1991; 26: 1137-1144
  • 14 Weickert U, Venzke T, Konig J et al. Why do bilioduodenal plastic stents become occluded? A clinical and pathological investigation on 100 consecutive patients. Endoscopy 2001; 33: 786-790
  • 15 Groen AK, Out T, Huibregtse K et al. Characterization of the content of occluded biliary endoprostheses. Endoscopy 1987; 19: 57-59
  • 16 van Berkel AM, van Marle J, Groen AK et al. Mechanisms of biliary stent clogging: confocal laser scanning and scanning electron microscopy. Endoscopy 2005; 37: 729-734
  • 17 Isayama H, Komatsu Y, Tsujino T et al. A prospective randomised study of “covered” versus “uncovered” diamond stents for the management of distal malignant biliary obstruction. Gut 2004; 53: 729-734
  • 18 Krokidis M, Fanelli F, Orgera G et al. Percutaneous treatment of malignant jaundice due to extrahepatic cholangiocarcinoma: covered Viabil stent versus uncovered Wallstents. Cardiovasc Intervent Radiol 2010; 33: 97-106
  • 19 Saleem A, Leggett CL, Murad H et al. Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. Gastrointest Endosc 2011; 74: 321-327
  • 20 Telford JJ, Carr-Locke DL, Baron TH et al. A randomized trial comparing uncovered and partially covered self-expandable metal stents in the palliation of distal malignant biliary obstruction. Gastrointest Endosc 2010; 72: 907-914
  • 21 Yoon WJ, Lee JK, Lee KH et al. A comparison of covered and uncovered Wallstents for the management of distal malignant biliary obstruction. Gastrointest Endosc 2006; 63: 996-1000
  • 22 Kullman E, Frozanpor F, Söderlund C et al. Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study. Gastrointest Endosc 2010; 72: 915-923
  • 23 Almadi MA, Barkun AN, Martel M. No benefit of covered vs uncovered self-expandable metal stents in patients with malignant distal biliary obstruction: a meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 27-37